

TABLE OF CONTENTS

Book 5

Preface	i
Editorial Board	ii
Book 5 Panel	iii
Continuing Education and Program Evaluation Instructions	viii
Roles of ACCP and BPS	xi

Science and Practice of Pharmacotherapy I

UNDERSTANDING STATISTICS: AN APPROACH FOR THE CLINICIAN

Learning Objectives	1
Introduction	1
Types of Data	1
Discrete Variables	2
Continuous Variables	3
Descriptive Statistics	3
Describing Central Tendency	3
Mean	3
Median	3
Mode	3
Describing Variability in Data	3
Standard Deviation	3
Range	4
Standard Error of the Mean	4
Testing Hypotheses Using Statistics	4
Conventions of Hypothesis Testing	4
The H_0	4
Statistical Significance	4
Clinical Significance	5
Decision Errors	5
The Two Types of Errors	5

Power	6
Approaches to Analyzing Clinical Trials	6
Intention to Treat	6
Per Protocol	6
As Treated	7
Confidence Intervals	7
Common Statistical Tests and Their Interpretation	8
Parametric Versus Nonparametric Tests	8
Categorical Variables	8
Ordinal Variables	9
Continuous Variables	9
Subgroup Analysis	10
Composite End Points	11
Statistical Techniques in Systematic Reviews (Meta-analysis)	11
Interpreting Results	11
Sensitivity Analysis and Heterogeneity	12
Characterizing Relationships Among Variables	12
Regression and Correlation	12
Multivariable Analysis/Regression	13
Survival Analysis	13
Interpreting Summary Reports of Effect	14
Absolute Versus Relative Changes	14
Number Needed to Treat	14
Putting Results into Perspective	14
Summary	15
Annotated Bibliography	15
Self-Assessment Questions	17

OVERVIEW OF OUTCOMES RESEARCH

Learning Objectives	21
Introduction	21
Theoretical Frameworks	22
Structure, Process, and Outcome Model	22
Economic, Clinical, and Humanistic Outcomes Model	23
Clinical Outcomes	24
Humanistic Outcomes	25
Economic Outcomes	25

Conceptual Framework of Outcomes Research	27
Model of the Impact of Outcomes Research	28
Types of Outcomes Research	29
Evaluations of Practice Variation	30
Descriptive Epidemiology Studies	30
Comparisons of Effectiveness	30
Economic Assessments	31
Modeling Studies	31
Assessment of the Quality of Care	31
Methodology Research	32
Studies of Patient-reported Outcomes	32
Studies of Behaviors and Attitudes in Health Care	33
Systematic Reviews and Meta-analyses	33
Health Policy Evaluations	33
Settings of Pharmacy-related Outcomes Research	34
Hospitals and Health Systems	34
Managed Care Organizations	35
Pharmaceutical Industry	35
Academic Institutions	37
Government Agencies	37
Conclusion	37
Annotated Bibliography	38
Self-Assessment Questions	39

SECONDARY DATA ANALYSIS/
OBSERVATIONAL RESEARCH

Learning Objectives	43
Introduction/Secondary Data Sources	43
Characteristics of Secondary Data Analysis	43
Advantages of Secondary Data Analysis	43
Disadvantages of Secondary Data Analysis	44
Key Issues in the Proper Conduct of Secondary	
Data Analysis	44
Adequacy of Data Sources	44
Measurement Validity and Reliability	45
Data Linkages and Eligibility Over Time	45
Research Validity	46
Internal Validity: Definition/Importance	46
Major Threats to Internal Validity	48
Threats Related to Equivalence of Study Groups	48
Threats Related to Effects of Variables Other	
than the Independent Variable of Interest	49
Limiting Threats to Internal Validity	49
Research Design	49
Case-matched Designs	50
Multivariable Analysis	51
Subclassification and Propensity Score Matching	52
External Validity/Generalizability	53
Applications of Secondary Data Analysis	53
Descriptive Data Analysis	53
Inferential Data Analysis	54
Human Subject Protections in Secondary Data	
Analysis	54
Belmont Report	54
Institutional Review Board/Definition of Research	54
Types of IRB Submissions	55

Informed Consent Requirements	55
The Health Insurance Portability and	
Accountability Act	56
De-identified Data	56
Waiver from HIPAA Regulations	56
Limited Data Set	56
Conclusion	57
Annotated Bibliography	57
Self-Assessment Questions	59

HEALTH STATUS ASSESSMENT IN RESEARCH AND
PRACTICE

Learning Objectives	65
Introduction	65
Quantity Versus Quality of Life	65
Defining and Measuring Health	66
Newer Conceptual Models	67
Identifying Published Health Status Questionnaires	67
Assess General Characteristics	68
Determine if the Questionnaire is Generic or	
Disease-specific	70
Combined Generic and Disease-specific	
Questionnaires	71
Assess the Domains and Range	71
Assess Psychometric Properties	71
Reliability	71
Validity	72
Face Validity	72
Content Validity	73
Criterion Validity	73
Construct Validity	73
Responsiveness	74
Response Bias	74
Other Considerations	74
Administration—When, Where, and How?	75
When	75
Where	75
How or Administration Methods	75
Self-administration	75
Mail Out/Mail Back	75
Computer-assisted Data Collection and	
Interactive Computer Technology	77
Audio-assisted Interviewing	77
Interviewer Administration	78
Telephone Interview Administration	78
Mixing Modes of Administration	79
Use of Health Status Measures in Clinical Practice	79
Considerations for Individual Patient Use	80
Considerations for Clinical Practice	80
General Questionnaire Characteristics to be	
Considered for Clinical Practice	80
Administration Methods for Clinical Practice	81
Computerized-adaptive Testing	81
Interpreting Health Status Results	82
Distribution-based Measures	82
Anchor-based Measures	82

Maintaining Patient Interest in Completing Questionnaires	.83
Implications of Health Status Assessment for Clinicians	.84
Health Status Assessment in Research	.84
Questionnaire Considerations Specific to Research	.84
Conclusion	.85
Annotated Bibliography	.85
Self-Assessment Questions	.87

Science and Practice of Pharmacotherapy II

LITERATURE EVALUATION

Learning Objectives	.93
Introduction	.93
Systematic Approach	.93
Tertiary References	.94
Secondary References	.94
How to Search Secondary References	.95
Primary References	.95
Bias, Validity, and Confounding Variables	.96
Clinical Trial Design	.96
Meta-analysis	.98
Consolidated Standards of Reporting Trials	
Statement	.99
Structure of a Randomized, Controlled Trial	.99
Title	.99
Author Affiliations	.99
Abstract	.99
Introduction	101
Methods	101
Inclusion and Exclusion Criteria	101
Interventions and Controls	102
Outcome Measures	102
Randomization	102
Blinding	103
Statistics	103
Sample Size	103
Interim Analysis	103
Intention-to-Treat Analysis	104
Results	104
Baseline Characteristics	104
Flow Diagram	104
Data and 95% Confidence Intervals	104
Discussion	105
References and Sponsorship	105
The Publication Process	105
Steps	105
Peer Review	105
Reasons for Revision	105
Fate of Rejected Articles	106
The Internet	106
How to Evaluate a Web Site	106
Health on the Net Foundation Code of Conduct	106
Useful Web Sites	107
Conclusions	107

Annotated Bibliography	109
Self-Assessment Questions	111

EVIDENCE-BASED PHARMACOTHERAPY

Learning Objectives	115
Introduction	115
The Evolution of Evidence-based Medicine	115
Criticisms of EBM	116
Applications of EBM	116
Top-down EBM	117
Overview	117
Framework	117
Types of Questions	117
Developing Answerable Questions	118
Gathering the Evidence	118
Appraising the Evidence	120
Incorporating Best Evidence into the Clinical Decision	121
Evaluating the Process	121
Strengths and Weaknesses of Top-down EBM	121
Bottom-up EBM	121
Overview	121
Framework	121
Developing Answerable Questions	121
Gathering the Evidence	122
Systems	122
Syntheses	122
Synopsis	123
Studies	123
Search Tools	124
Appraising the Evidence	124
Incorporating Best Evidence into the Clinical Decision	124
Evaluating the Process	125
Strengths and Weaknesses of Bottom-up EBM	125
Conclusion	125
Annotated Bibliography	125
Self-Assessment Questions	127

CLINICAL BIOETHICS IN PHARMACY PRACTICE

Learning Objectives	131
Introduction	131
Foundations of Clinical Bioethics Applicable to Pharmacy Practice	132
Historical and Evolutionary Aspects	132
Methods of Justification in Clinical Bioethics	133
Theories, Principles, and Rules	134
Moral Theories	134
Utilitarian Theory	135
Deontological Theory	135
Liberal Individualism Theory	135
Communitarian Theory	136
Ethics of Care Theory	136
Principles	136
Respect for Autonomy	136
Nonmaleficance	137

Beneficence	138
Justice	138
Rules	139
Veracity	139
Fidelity	140
Rule Conflicts	140
Criticisms of Principles and Rules in Clinical Bioethics	140
Codes of Ethics	141
Connecting Clinical Bioethics to Pharmacy Practice	142
Clinical Bioethics and the Six Aims of Health Care	143
The Six Aims	143
Clinical Bioethics Concepts Underlying the Six Aims	144
Clinical Bioethics and Pharmaceutical Care	144
Pharmaceutical Care	144
Clinical Bioethics Concepts Underlying Pharmaceutical Care	145
Application of Clinical Bioethics to Pharmacy Practice	146
Connecting Clinical Bioethics to Managed Care Pharmacy Practice	146
Managed Care Pharmacy Practice	146
Prescription Drug Benefit Coverage Policies	147
Payer Organization Objectives	147
Ethically Justifiable Prescription Drug Benefit Coverage Policies	148
An Ethical Template	148
Contexts for Allocation Processes	149
Prescription Drug Benefit Management Practices	149
Providing Information	149
Adjudication of Benefit Coverage Policies	150
Capturing Cost Advantages	150
Applicable Clinical Bioethics Concepts	151
Conclusion	152
Acknowledgement	153
Annotated Bibliography	153
Self-Assessment Questions	155

Science and Practice of Pharmacotherapy III

HEALTH PROMOTION AND DISEASE PREVENTION	
Learning Objectives	165
Introduction	165
Government Initiatives in Public Health	166
Developing Disease Prevention Programs	166
Centers for Disease Control and Prevention Initiatives	167
Food and Drug Administration Initiatives and Regulations	168
Pharmacogenomics and Disease Prevention	169
Tobacco Use	170
Primary Prevention of Chronic Disease	170
Obesity	171
Pharmacotherapy for Obesity	171

Surgical Treatments of Obesity	172
Hormone Therapy	173
Preterm Labor	173
Hydroxyprogesterone Caproate	174
Tocolytic Therapy	174
Recurrent Pregnancy Loss	174
Preventing Drug-induced Birth Defects	175
Pregnancy and Live Vaccines	176
Isotretinoin	176
Thalidomide	176
Fetal Alcohol Syndrome	177
How to Counsel Pregnant Alcoholic Women	177
Targeted Media Campaigns to Reduce FAS	178
Preventing Substance Abuse Among Children and Adolescents	179
Risk Factors and Protective Factors	179
Treatment of Opiate Dependence with Buprenorphine	181
Conclusions, Challenges, and More Questions	182
Annotated Bibliography	182
Self-Assessment Questions	185

PHARMACOGENOMICS

Learning Objectives	189
Introduction	189
Interpatient Variability in Drug Response	189
Limitations to the Current Pharmacological Approach to Disease Management	189
Pharmacogenomics	190
Definition	190
Pharmacogenetics Versus Pharmacogenomics	190
Goals	191
Genetic Concepts	191
Structure of DNA	191
Nucleotide	191
Codon	191
Gene	191
Allele	191
Haplotypes and Linkage Disequilibrium	191
Polymorphisms	192
Types	192
Sites	192
Pharmacokinetic and Pharmacodynamic Consequences	192
Polygenic Influences of Drug Response	192
Drug-metabolizing Enzymes	193
Cytochrome P450 Enzymes	193
Cytochrome P450 2B6	194
Cytochrome P450 2C9	194
Cytochrome P450 2C19	194
Cytochrome P450 2D6	194
Other Phase I Enzymes	195
Alcohol and Aldehyde Dehydrogenases	195
Phase II Enzymes	195
N-Acetyltransferase	195
Glutathione S-Transferase	196

Uridine Diphosphate Glucuronosyltransferase . . .	196	Cardiac Ion Channel Genes and Drug-induced	
Nucleotide Base-metabolizing Enzymes	196	Torsade de Pointes	205
Thymidylate Phosphorylase	196	Genes Associated with Disease Severity and	
Dihydropyrimidine Dehydrogenase	197	Response to Statins in Coronary Heart Disease . .	206
Thiopurine Methyltransferase	197	Application of These Data to Clinical Practice . . .	206
Application of These Data to Clinical Practice . . .	197	Contraceptive Methods	206
Flushing Syndrome with Ethanol Consumption . .	197	Drugs with Propensity to Cause QT Interval	
Mercaptopurine in Acute Lymphoblastic		Prolongation	206
Leukemia	197	Primary and Secondary Prevention of Coronary	
Fluorouracil in Colorectal Cancer	197	Events	207
Irinotecan in Colorectal Cancer	198	Ethical and Regulatory Issues	207
Warfarin in Thromboembolic Disease	198	Ethical Issues	207
Commercially Available CYP Genotype Tests . .	198	Regulatory Issues	207
Drug Transporter Genes	199	Impact of Pharmacogenomics on Pharmacy	
Function of Drug Transporter Proteins	199	Practice	207
P-glycoprotein	199	Timeline for Integration of Pharmacogenomics into	
Definition	199	Practice	207
Drug Substrates	199	Skills of the Competent Pharmacist in the Age of	
Multidrug Resistance 1 Gene	200	Pharmacogenomics	208
Effects on Digoxin Distribution	200	Summary	208
Effects on the Distribution and Response to Protease		Annotated Bibliography	208
Inhibitors	200	Self-Assessment Questions	211
Other Transporter Genes	200		
Multidrug Resistance Proteins	200	BIOTERRORISM	
Dipeptide Transporters	201	Learning Objectives	215
Application of These Data to Clinical Practice . .	201	Introduction	215
Digoxin Treatment in Heart Failure and Atrial		Historical Perspectives	215
Arrhythmias	201	Current Threats	215
Human Immunodeficiency Virus Therapy with		Anthrax	216
Protease Inhibitors	201	Pathogen/Epidemiology	216
Drug Target Genes	201	Method of Transmission	216
Description	201	Diagnosis	216
Receptor Genes	202	Clinical Presentation	217
β_1 -Adrenergic Receptor Gene and β -Blocker		Treatment	217
Response in Hypertension	202	Postexposure Prophylaxis	219
Neurotransmitter Receptor Gene and Clozapine		Smallpox	219
Response in Schizophrenia	202	Pathogen/Epidemiology	219
Enzyme Genes	203	Method of Transmission	219
Angiotensin-converting Enzyme Gene and ACE		Diagnosis	220
Inhibitor Response in Hypertension	203	Clinical Presentation	220
Angiotensin-converting Enzyme Gene and ACE		Treatment	221
Inhibitor-induced Cough	203	Postexposure Prophylaxis	221
Intracellular Signaling Protein Genes	204	Plague	221
G-Protein β_3 Subunit Gene and Diuretic		Pathogen/Epidemiology	221
Response in Hypertension	204	Method of Transmission	221
G-Protein β_3 Subunit Gene and Antidepressant		Diagnosis	222
Response	204	Clinical Presentation	222
α -Adducin Gene and Diuretic Response in		Treatment	222
Hypertension	204	Postexposure Prophylaxis	222
Application of These Data to Clinical Practice . .	204	Botulism	222
Hypertension Management	204	Pathogen/Epidemiology	222
Depression Management	204	Method of Transmission	224
Schizophrenia Management	205	Diagnosis	224
Disease-associated Genes	205	Clinical Presentation	224
Coagulation Factor Genes and Thromboembolic		Treatment	224
Events with Oral Contraceptives	205	Postexposure Prophylaxis	225

Viral Hemorrhagic Fever	225
Pathogen/Epidemiology	225
Method of Transmission	225
Diagnosis	225
Clinical Presentation	225
Treatment	225
Postexposure Prophylaxis	226
Tularemia	226
Pathogen/Epidemiology	226
Method of Transmission	226
Diagnosis	226
Clinical Presentation	227
Treatment	227
Postexposure Prophylaxis	228
Monitoring Parameters	228
Vaccinations	228
Anthrax	228
Overview	228
Safety	229
Current Status	229
Smallpox	229
Overview	229
Safety	230
Current Status	231
Emergency Preparedness	231
National Pharmacist Response Team	231
Responsibilities	231
Strategic National Stockpile	232
Purpose	232
Push Packages	232
Contents	232
Deployment	232
Distribution Strategies	232
Institution-specific Preparedness	232
Role of the Pharmacist	232
Considerations for Inventory	232
Suggested Formulary	232
Drug Shortages	233
How to Report a Threat	233
Resources for Bioterrorism Information	233
Publications	233
Internet Resources	233
Conclusion	233
Annotated Bibliography	234
Self-Assessment Questions	237